GSK claims that Pfizer’s FDA-approved vaccine for respiratory syncytial virus infringes on four patents protecting its own approved vaccine, Arexvy. The patent suit comes with the RSV season ...

A study by former Junior Associate Professor Kazuo Takayama, currently a professor of the Institute of Science Tokyo, ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

Common respiratory condition nearly triples the risk of death in adults, new study finds A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial ...

Coronavirus and respiratory syncytial virus (RSV) are two kinds of respiratory viruses that can infect you and have similar symptoms. It can be hard to tell the difference between infections ...

Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their households, based on data from more than 3000 individuals. Previous studies ...

Every year, millions of infants are infected by a little-known virus that is the most common cause of respiratory disease in children. Respiratory syncytial virus (RSV) (Fig. 1) causes a spectrum ...

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...